MarketPulse

biotech acquisition

2 articles
The Motley FoolThe Motley Fool··Thomas Niel

Viking Therapeutics' VK2735 Could Reshape Weight Loss Market—If Phase 3 Succeeds

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.
PFELLYNVOVKTXclinical trialsVK2735
The Motley FoolThe Motley Fool··Jonathan Ponciano

Cormorant's $64M Arcellx Exit Preceded 77% Gilead Takeover Surge

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.
GILDACLXfund exitoncology